Member Info for Bermudashorts

Moonparty,

Re. your 16.47/16.47 - there are only a few vaccines in development targeting both the S & N proteins and very, very few I could find that are actually in clinical trials. In terms of how their approach compares to Scancell:-

Two of the most advanced in development (ImmunityBio and Vaxart) use adenovirus vectors - similar to AstraZeneca but a human rather than chimpanzee form. On the plus side this is tried and tested technology but drawbacks are that adenovirus-vectored vaccines aren't so easy to manufacture and could trigger an immune reaction to the vector itself resulting in reduced efficacy. There are some known serious (but very, very rare) side effects.

Gritstone are using a self-amplifying mRNA vaccine targeting both the S & N proteins - once injected, the mRNA is self-replicating so should require lower doses than the existing Pfizer/Moderna mRNA vaccines. I believe Gritstone are using lipid nanoparticles to deliver their vax and assume that like the other mRNA vaccines, this will require cold storage and has the same stability issues.

Finally, like Scancell, Genexine are developing a DNA vaccine but theirs is delivered via electroproation.

So a few different approaches and it'll be interesting to see how they all play out. So far the concept of targeting both proteins looks very promising and it will be great news for Scancell if/when any of these trials produce positive results.

Ivy/Crumbs,

Yes, I don't think Scancell have published any data but very reassuring to read the words ' strong binding to the Delta variant' and even more so as it was in relation to both SCOV1 and SCOV2.

Not invested in POLX but I believe they were applying for approval for a system which had been designated a combination drug-device product by the FDA. When applying for approval, all new drug applications are allocated a PDUFA date by the FDA. I can explain what it stands for, but it doesn't really matter, it's simply the date by which they'll make a decision. I don't think this happens with new medical device applications which are handled by a different department of the FDA.

I'm sure there'll be some here who are/were also invested in POLX and can correct me if I'm wrong, but I assume that Polarean were simply going by the PDUFA date issued by the FDA.

WTP well spotted thanks

Chester,

Hopefully there will be an interim update after all patients have been vaccinated with both doses of SCOV1 and before they are boosted with SCOV2. The second SCOV1 dose is given 4 weeks after the first but they'll obviously need some time to collate, verify and analyse results after the last patient has received their second dose. So I don't think we'll have to wait for April but might not be as quick as the 4 to 6 weeks moonparty is expecting!

As for the UK Covidity trial, I'm not sure whether that can run in parallel with the SA SCOV2 booster trial or whether they'll need to complete the South African trial first. In other words, I'm not sure whether the MHRA will want to see SCOV2 clinical safety data from South Africa before giving clinical trial approval for the UK study or whether they'd be happy to accept the SCOV1 data. I guess all will be clarified at the AGM.

Really interesting research here from Prof. Hebebrand, University of Duisburg-Essen - to be presented at a conference tomorrow.

Based on the fact that the hormone leptin is the major endocrine signal for starvation, he prescribed Amryt's Metreleptin (MYalept/Myalepta) off-label to 11 patients suffering from Anerexia Nervosa with what appear to be very encouraging results:-

'We observed a rapid onset of beneficial effects on AN specific cognitions, emotions and behaviors.'

'The seemingly strong psychopharmacological effects of metreleptin warrant further investigation.'

Clearly clinical trials are required but would be fantastic if Metreleptin has a role to play in helping patients battle AN.

https://www.chumontreal.qc.ca/en/crchum/nouvelles/rapid-and-pronounced-clinical-improvement-patients-anorexia-nervosa-upon-treatment-human

correction - if the FDA were biased

lse admin. - please, please sort out an edit function

SK,

Have lost count of the number of posts I've read about FDA bias towards either US companies or big pharma but nobody to date has supplied a scrap of evidence in support of that view. There is a high degree of alignment with the EMA when it comes to new drug approvals which sort of disproves the theory. If the FDA were bias then the Europeans would have a much higher rate of approval.

Kashdog/Ruck,

I don't think I've ever been invested in a bio that hasn't issued an RNS for the first patient dosed in a clinical trial and from memory they have all been a regulatory RNS rather than RNS REACH. Worth also noting that both BioNTech and Moderna make 6K/8K SEC filings when first patients are dosed on their trials.

What sort of information merits an RNS for a pharma giant like AZN is not necessarily the same as for a baby bio and I assume Scancell's nomad considered the news worthy of an RNS.

Excellent news and great to see Scancell dosing patients in the clinic again. Even better that recruitment and SCOV1 dosing should be quick.

yuyus

Here is the obituary for David Newland - clearly an exceptional man.

https://www.thetimes.co.uk/article/professor-david-newland-obituary-87rmj5857

Cleanerworld,

I think it's probably more likely he was referring to either ImmunityBio or Vaxart, both of which have vaccines targeting the N protein, have completed phase I trials and are currently running various phase II studies.

His name is Andrew Ustianowski.

Ray,

Yep, a strange comment. Angle also are focusing on breast and ovarian cancer, and in general breast cancer receives around twice as much research funding as prostate cancer.

Another strong set of results -

- Total revenue growth of 38.8% over H1 2020 to £56.0 million (up 48.1% in constant currency*)
- adjusted EBITDA of £12.1 million up 33.0%
- Net new sales awards in H1 2021 increased by 50.8% over H1 2020
- Cash balance increased to £24.6 million and debt free

Looks like Amryt are gearing up for FDA approval, they're now recruiting sales professionals in the US specifically for Filsuvez

https://www.linkedin.com/jobs/view/rare-disease-specialist-rds-filsuvez%C2%AE-oleogel-s10-at-amryt-pharma-plc-2729693995

Agree and worth noting that Angle release all of these research updates as RNS Reach.

Kevin, maybe that was a different award - shortlist only announced today.

Not sure whether this has already been posted but Synairgen have been shortlisted for this year's Scrip Awards in the Covid-19 pandemic clinical advance of the year category. The others shortlisted in the same category are BioNTech/Pfizer and Modernal for their covid vaccines and also Regeneron for their monoclonal antibodies. Details below.

https://pharmaintelligence.informa.com/events/awards/scrip-awards-2021/shortlist

gawdhelpus

The fact that the patients in the Royal Marsden trial require radiotherapy in the first place means that they have been diagnosed with prostate cancer via a tissue biopsy and their cancer is severe enough to require radical radiotherapy. Angle have highlighted a potential role for Parsortix in the initial diagnosis of prostate cancer (see link below) and also in genetic analysis and ongoing monitoring of patients' CTCs.

So in answer to your question, I guess there's always the potential for any oncology clinical trial to benefit from ongoing monitoring of CTCs but other than that, I don't see any impact for Angle. Great news for patients though if it works.

https://angleplc.com/translational-research/mens-health/prostate-cancer/

Burble - thanks, appreciated.

So research was funded by Scancell and a couple of excerpts:-

'There is accumulating evidence that citrullination is implicated in cancer development and can be an excellent target to alert the immune response to recognise and remove stressed cells including cancer cells'

'Cancer vaccines targeting citrullinated vimentin and/or enolase maybe a good therapy for CRC patients expressing high levels of PAD enzymes'

Suggests that CRC patients most likely to respond to Moditope can be pre-selected based on PADI2 and PADI4 expression - is that correct Burble?